Market Overview

UPDATE: Aegis Capital Downgrades SciClone Pharmaceuticals to Hold on Financial Restatement Due to NovaMed Accounting Errors

Related SCLN
SciClone To Pursue Development Of SGX942 In China Following Soligenix' Report Of Positive Phase 2 Preliminary Results In Oral Mucositis
Mid-Afternoon Market Update: Dow, S&P 500 Turn Higher; Scientific Games Shares Drop Following Q3 Results

In a report published Monday, Aegis Capital downgraded its rating on SciClone Pharmaceuticals (NASDAQ: SCLN) from Buy to Hold.

Aegis Capital noted, “SciClone recently announced that it will restate the financial statements for Q2-Q3 of 2011 and Q1-Q3 of 2012 due to accounting errors in its China subsidiary NovaMed. According to the firm, this will likely increase 9-month 2012 revenue by ~$3mm and before-tax income by ~$2mm, as well as decrease FY2011 revenue by ~$1mm and before-tax income by <$1mm. The issue primarily pertains to the timing of Pfizer products revenue recognition within NovaMed, which was effectively a “sell-through” method as opposed to the “sell-in” method originally drafted with the distributor. The Pfizer products had combined revenue of ~$9mm for FY2011 and 9-month 2012. The accounting issue also pertains to recognition of product return reserves for Aggrastat, another product sold by NovaMed. Aggrastat had combined revenue of ~$3.6mm for FY2011 and 9-month 2012. The restatement is slated to be presented with the coming 10-K. On a separate note, SciClone's auditor Ernst & Young decided not to stand for re-appointment after the restatement and 2012 10-K. In the wake of this news and the uncertainty the firm faces in securing another prestigious public accounting firm to act as auditor, we are downgrading our rating to Hold without a price target on SCLN shares.”

SciClone Pharmaceuticals closed on Friday at $4.82.

Latest Ratings for SCLN

Jun 2015MLV & Co.Initiates Coverage onBuy
Nov 2014BWS FinancialDowngradesBuyHold
Jul 2013Aegis CapitalUpgradesHoldBuy

View More Analyst Ratings for SCLN
View the Latest Analyst Ratings

Posted-In: Aegis CapitalAnalyst Color Downgrades Analyst Ratings


Related Articles (SCLN)

Get Benzinga's Newsletters